Free Trial

Longboard Pharmaceuticals Q2 2023 Earnings Report

Longboard Pharmaceuticals EPS Results

Actual EPS
-$0.65
Consensus EPS
-$0.61
Beat/Miss
Missed by -$0.04
One Year Ago EPS
N/A

Longboard Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Longboard Pharmaceuticals Announcement Details

Quarter
Q2 2023
Time
N/A

Longboard Pharmaceuticals Earnings Headlines

H. Lundbeck A/S (HLUN-A.CO)
WARNING: “Buffett Indicator” flashing for first time in 50 years
Warren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash. His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.
See More Longboard Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Longboard Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Longboard Pharmaceuticals and other key companies, straight to your email.

About Longboard Pharmaceuticals

Longboard Pharmaceuticals (NASDAQ:LBPH), a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. The company develops bexicaserin (LP352), which has completed Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. It also develops LP659, an S1P receptor modulator for the treatment of neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.

View Longboard Pharmaceuticals Profile

More Earnings Resources from MarketBeat